Involvement of LeMDR, an ATP-binding cassette protein gene, in shikonin transport and biosynthesis in Lithospermum erythrorhizon

Yu Zhu,G. Lu,Zhuo-Wu Bian,Feng-Yao Wu,Y. Pang,Xiao-Ming Wang,Rongwu Yang,Cheng-Yi Tang,J. Qi,Yong-Hua Yang

DOI: https://doi.org/10.1186/s12870-017-1148-6

IF: 5.26

2017-11-13

BMC Plant Biology

Abstract:

What problem does this paper attempt to address?

EFFECT OF ADJUVANT ENDOCRINE THERAPY ON ESTROGEN RECEPTOR-NEGATIVE, PROGESTERONE RECEPTOR-POSITIVE AND HER2 NEGATIVE BREAST CANCER PATIENTS

Jun Shen,Lin-bo Wang,Rong-yue Teng,Jian-guo Shen

DOI: https://doi.org/10.19193/0393-6384_2022_3_241

2022-01-01

Acta medica mediterranea

Abstract:Objective: The purpose of this study was to analyze the efficacy of adjuvant endocrine therapy in ER-negative, PR positive and human epidermal growth factor receptor-2 (HER2) negative (ER-/PR+, HER2-) breast cancer patients retrospectively. Methods: In this single-center retrospective study, 1348 female HER2 negative breast cancer patients who were treated from August 1st, 1996 to April 30th, 2016 were included. Patients were characterized as "HER2 negative" if the semi-quantitative score of human epidermal growth factor receptor-2 (HER2) was absent or showed weak or incomplete membrane staining in breast cancer tissue. Tissue which was classified as ER or PR positive had 1% or more cells with nuclear staining as determined by immunohistochemical analysis. "HER2 negative" patients were divided into three subgroups based on the expression level of ER and PR: ER+/PR (+,-), ER-/PR+ and ER-/PR-. The clinical characteristics of each patient were investigated, cumulative survival rates of the three subgroups were analyzed by the Kaplan-Meier method, and the differences in cumulative survival was assessed using the Log-rank method. Results: The 5-year overall survival rates of all patients in the study were 88%; with 92%, 90% and 87% of those in ER+/PR (+,-), ER-/PR+ and ER -/PR-groups respectively living longer than 5 years. The 5-year overall survival rates among the three subgroups were significantly different (P=0.047) as determined by univariate analysis. However, no significant difference was found between ER-/ PR+ and ER -/PR-groups (P=0.35). Conclusion: Taken together, ER-/PR+ female breast cancer patients may have improved survival outcomes from adjuvant endocrine therapy.
Endocrine Therapy As Adjuvant or Neoadjuvant Therapy for Breast Cancer: Selecting the Best Agents, the Timing and Duration of Treatment

Jun Jie Li,Zhi Min Shao

DOI: https://doi.org/10.21037/cco.2016.03.24

2016-01-01

Chinese Clinical Oncology

Abstract:Hormone receptor (HR) positive breast cancers represent the vast majority of breast cancers. Adjuvant and/or neoadjuvant endocrine therapy is highly effective and appropriate for nearly all women with HR positive tumors. Adjuvant tamoxifen (TAM) is a major endocrine treatment option, which has been found to be effective in both premenopausal and postmenopausal patients. Considerable evidence has been accrued of a benefit for ovarian ablation or suppression (OA/S) in premenopausal patients, for aromatase inhibitors (AIS) in postmenopausal patients, for the longer duration of adjuvant endocrine therapy and for the clinical utility of neoadjuvant endocrine therapy. Clinical practice guidelines should keep changing with developing evidence-based practice guidelines pertaining to breast cancer care. The present publication conducted a comprehensive systematic review of the literature addressing the use of endocrine therapy as adjuvant or neoadjuvant therapy for HR positive breast cancer, focusing on selecting the best agents for both premenopausal and postmenopausal patients, as well as the optimal duration of such treatment.
[Neoadjuvant endocrine therapy for locally advanced breast cancer]

G Viola,D Sergi,F Conti,M Lopez

Abstract:The use of neoadjuvant chemotherapy in the treatment of locally advanced breast cancer is now well established. However, endocrine therapy can be a valid alternative to primary chemotherapy in the treatment of hormone-sensitive tumors, particularly in post-menopausal women. Tamoxifen (TAM) was initially used in older or frail patients who were not candidates for chemotherapy. Response rate of 49% to 68% were observed. These encouraging results prompted subsequent randomized phase III studies demonstrating the superiority of surgery in comparison to TAM as primary treatment. The successful use of aromatase inhibitors (AI) in the metastatic and adjuvant setting has encouraged studies that compare these agents with tamoxifen in the neoadjuvant setting. In terms of response rates, anastrozole and exemestane did not differ from TAM, while letrozole was superior. Nevertheless, all the AI were found to be superior to TAM as far as breast conserving surgery is concerned. The Americal College of Surgeons Oncology Group (ACOSOG) has recently activated a neoadjuvant randomized trial comparing anastrozole, letrozole and exemestane in postmenopausal patients with estrogen receptor positive tumors. Hopefully, this study will clarify which of these agents is more effective as primary endocrine therapy. In the meantime, neoadjuvant hormonal treatment should be considered in elderly patients with inoperable tumors or tumors not amenable to conservative surgery, with highly expressed estrogen receptors and contraindication to chemotherapy.
Abstract P2-03-19: The efficacy of neoadjuvant endocrine therapy during the waiting period for surgery in postmenopausal hormone receptor positive breast cancer

Yuka Maeda,Saki Naruse,Yuka Isono,Ayana Sato,Miki Yamada,Akiko Matsumoto,Tatsuhiko Ikeda,Hiromitsu Jinno

DOI: https://doi.org/10.1158/1538-7445.sabcs22-p2-03-19

IF: 11.2

2023-03-04

Cancer Research

Abstract:Background: Although neoadjuvant endocrine therapy has been used to improve breast conservation rate, its prognostic relevance is unknown. The search for a valid prognostic factor equivalent to pCR in neoadjuvant chemotherapy is a current challenge in neoadjuvant endocrine therapy. In this study, we investigated the efficacy of short term neoadjuvant endocrine therapy utilizing the waiting period for surgery and the prognostic factor including Preoperative Endocrine Prognostic Index (PEPI) score. Patients and Methods: A total of 269 postmenopausal women with hormone receptor-positive, HER2-negative breast cancer was treated with endocrine therapy with non-steroidal aromatase inhibitor during the waiting period for surgery between October 2012 and November 2021. Of the entire 269 patients, 92 and 177 patients had anastrozole and letrozole, respectively. The primary endpoint was change in tumor size by ultrasound and Ki67 before and after short-term endocrine therapy. The secondary endpoint was prognosis of patients divided by PEPI score which was calculated using tumor size, lymph node metastasis, Ki67, and ER Allred score. This study was approved by the institutional review board of Teikyo University. Results: Median age was 68 years old (range, 41-89). ER and PgR was positive in 266 (98%) and 232 (86%) of the entire 269 patients, respectively. Median tumor size was 1.65 cm (range, 0.4-7.5). Seventeen (6.3%) pts were clinically node-positive. Patients with histological grade I tumor were 190 (70.6%). The median duration of endocrine therapy was 39 days (range, 2-88). Average pretreatment Ki67 expression was 10% (range, 0-90). Tumor diameter was significantly decreased to 1.43cm (range,0.45-5.83) after short-term endocrine therapy (p=0.01). The Ki67 expression was significantly decreased to 3.0% (range, 0-85) after endocrine therapy (p< 0.01) and only five patients (1.9%) showed marked increase in Ki-67 expression. PEPI score 0, 1-3 and ≥ 4 was found in 83 (30.9%),147 (54.7%) and 39 patients (14.5%), respectively. After the median observation period of 928 days, patients with PEPI score ≥ 4 showed worse disease-free survival (Figure) compared with patients with PEPI score 0 and 1-3 (p=0.06). In terms of mortality, patients with PEPI score ≥ 4 had worse overall survival than patients with PEPI score 0 and 1-3 (p=0.07). Conclusions: These results suggested that neoadjuvant endocrine therapy during the waiting period for surgery might be effective in reducing the size and Ki67 expression level and PEPI score might be useful in predicting the prognosis of postmenopausal hormone receptor positive breast cancer patients. Citation Format: Yuka Maeda, Saki Naruse, Yuka Isono, Ayana Sato, Miki Yamada, Akiko Matsumoto, Tatsuhiko Ikeda, Hiromitsu Jinno. The efficacy of neoadjuvant endocrine therapy during the waiting period for surgery in postmenopausal hormone receptor positive breast cancer [abstract]. In: Proceedings of the 2022 San Antonio Breast Cancer Symposium; 2022 Dec 6-10; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2023;83(5 Suppl) nr P2-03-19.

oncology
Optimizing the Use of Neoadjuvant Endocrine Therapy

Laila S. Agrawal,Ingrid A. Mayer

DOI: https://doi.org/10.1007/s11912-015-0455-z

2015-05-26

Current Oncology Reports

Abstract:Nowadays, neoadjuvant endocrine therapy is a clinically acceptable (and sometimes preferred) strategy in patients with operable estrogen receptor-positive (ER+) breast cancer. Despite the overall effectiveness of endocrine therapy in breast cancer in all settings, de novo (primary) and acquired (secondary) endocrine therapy resistance remains a major clinical problem. Neoadjuvant endocrine therapy trials for breast cancer are not only a great opportunity to determine which ER+ breast cancers can be treated without chemotherapy, but also a great strategy to develop insights into the biologic basis for the efficacy of estrogen-receptor-targeting agents, alone or in combination, in an effort to counteract resistance to endocrine therapy and discover actionable molecular targets that can be the focus of future drug discovery efforts and/or translational/clinical investigation in ER+ breast cancers.

oncology
Phase 2 randomized trial of primary endocrine therapy versus chemotherapy in postmenopausal patients with estrogen receptor-positive breast cancer

Vladimir F Semiglazov,Vladislav V Semiglazov,Garik A Dashyan,Elena K Ziltsova,Vadim G Ivanov,Alla A Bozhok,Olga A Melnikova,Ruslan M Paltuev,Alexander Kletzel,Lev M Berstein

DOI: https://doi.org/10.1002/cncr.22789

IF: 6.9209

2007-07-15

Cancer

Abstract:Background: Few studies have compared primary neoadjuvant endocrine therapy with neoadjuvant chemotherapy in breast cancer patients. The need for preoperative chemotherapy with doxorubicin or taxanes may be reduced in postmenopausal patients with estrogen receptor (ER)-positive and/or progesterone receptor (PgR)-positive tumors. This randomized, controlled, phase 2 study evaluated the efficacy of neoadjuvant chemotherapy compared with endocrine treatment with aromatase inhibitors in postmenopausal women with ER-positive and/or PgR-positive breast cancer. Methods: Eligible patients were randomly assigned to receive neoadjuvant anastrozole 1 mg/day (n = 61) or exemestane 25 mg/day (n = 60) for 3 months or doxorubicin 60 mg/m(2) with paclitaxel 200 mg/m(2) (four 3-week cycles). Study end points included overall objective response determined by palpation, mammography, and ultrasound, and the number of patients who qualified for breast-conserving surgery and radiotherapy. Results: Clinical objective response was 64% in the endocrine therapy and chemotherapy treatment groups. Median time to clinical response was 57 and 51 days with aromatase inhibitors and chemotherapy, respectively (P > .05). Rates of pathological complete response (3% vs 6%) and disease progression (9% vs 9%) did not differ significantly in the endocrine therapy or chemotherapy group, respectively (P > .05). Rates of breast-conserving surgery were slightly higher in the endocrine group (33% vs 24%; P = .058). The most frequent toxicities from chemotherapy were alopecia (79%), grade 3/4 neutropenia (33%), and grade 2 neuropathy (30%). Endocrine treatment was well tolerated. No deaths occurred during the preoperative treatment. Conclusions: Preoperative neoadjuvant endocrine therapy with aromatase inhibitors was well tolerated and resulted in rates similar to chemotherapy in overall objective response and breast-conserving surgery in postmenopausal women with ER-positive and/or PgR-positive tumors.
Abstract ED01-01: Optimizing endocrine therapy in premenopausal women

V. Stearns

DOI: https://doi.org/10.1158/1538-7445.sabcs23-ed01-01

IF: 11.2

2024-05-03

Cancer Research

Abstract:Premenopausal women with early-stage hormone receptor (HR)-positive breast cancer are candidates for adjuvant endocrine therapy and have several treatment options. The clinical team should assess an individual woman's risk of recurrence, estimate benefits from specific endocrine manipulations, and consider co-morbidities, adverse event profile and host factors. Risk stratification strategies including clinic-pathologic features, genomic assays and composite scores can guide recommendations regarding type and duration of endocrine therapy, in particular in node-negative disease. Adjuvant tamoxifen for 5 to 10 years significantly reduces breast cancer recurrence and death. Premenopausal women who are at high risk of recurrence benefit from ovarian function suppression (OFS) with tamoxifen or an aromatase inhibitor for 5 years. Those include women with high-risk clinico-pathological features and younger age, and for whom chemotherapy is commonly recommended. There are currently no available data regarding the use of extended OFS beyond 5 years. Newer data support the addition of CDK 4/6 inhibitors to endocrine therapy in women with high-risk disease. Endocrine therpay is associated with frequent bothersome and few significant side effects that can negatively impact quality of life and adherence to treatment. Clinicians must carefully weigh the benefits associated with specific endocrine therapies, and possible short- and long-term side effects to individualize therapy, and to consider interventions to enhance adherence. Citation Format: V. Stearns. Optimizing endocrine therapy in premenopausal women [abstract]. In: Proceedings of the 2023 San Antonio Breast Cancer Symposium; 2023 Dec 5-9; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2024;84(9 Suppl) nr ED01-01.

oncology
[The use of GnRH analogues in early and advanced breast carcinomas].

F. Selle,N. Do Huyen,A. Esteso,K. Beerblock,J. Lotz,G. Emile,J. Gligorov,D. Avenin,C. Segura

Gynécologie Obstétrique & Fertilité

Abstract:Breast cancer is often an estrogen-dependent disease. The primary goals of the treatment of breast carcinomas are multiple, depending on the situation in which the patients are treated. In adjuvant setting, the aims are to delete the time of relapse, to increase the overall survival, and to offer to the patients the best quality of life they may expect. Tamoxifen is the standard hormonal agent for premenopausal women with receptor-positive breast cancer. Recent data show an increasing role for aromatase inhibitors in postmenopausal women. In metastatic setting, the primary goals are improved quality of life and prolonged survival; effective therapies with minimal toxicity, such as endocrine therapy, are highly desirable and should be considered a primary option over chemotherapy for selected estrogen-receptor positive patients. Ovarian ablation has been worldwide used. Methods of irreversible ovarian ablation include surgical oophorectomy and ovarian irradiation. Potentially reversible castration can be medically accomplished using luteinizing hormone releasing hormone analogues (LHRH agonists). In the metastatic setting, ovarian ablation (induced by the use of LHRH agonists or by surgical ovarian ablation) and tamoxifen monotherapies produce comparable outcomes, and may be more effective when used together (combined estrogen blockade). In advanced breast cancer, the combination prolongs the progression-free survival and increases response rates and duration of response rate relative to the use of LHRH agonist alone. In the adjuvant setting, data suggest that ovarian ablation followed by tamoxifen produces similar results to those obtained with adjuvant chemotherapy in hormone-receptor positive breast cancer women. The value of combining these modalities remains unclear, but the addition of the LHRH analogue goserelin to standard treatment results in a significant benefit in terms of relapse-free and overall survival, especially for estrogen-receptor positive patients. Finally, considering the efficacy of the new aromatase inhibitors, the interest of combining these drugs with the LHRH analogues has yet to be defined, both for pre- and post-menopausal patients.

Medicine
Neoadjuvant endocrine therapy in postmenopausal women with HR+/HER2- breast cancer

Carlos Martínez-Pérez,Arran K Turnbull,Charlene Kay,J Michael Dixon

DOI: https://doi.org/10.1080/14737140.2023.2162043

2023-01-21

Expert Review of Anticancer Therapy

Abstract:While endocrine therapy is the standard-of-care adjuvant treatment for hormone receptor-positive (HR+) breast cancers, there is also extensive evidence for the role of pre-operative (or neoadjuvant) endocrine therapy (NET) in HR+ postmenopausal women. We conducted a thorough review of the published literature, to summarize the evidence to date, including studies of how NET compares to neoadjuvant chemotherapy, which NET agents are preferable, and the optimal duration of NET. We describe the importance of on-treatment assessment of response, the different predictors available (including Ki67, PEPI score, and molecular signatures) and the research opportunities the pre-operative setting offers. We also summarize recent combination trials and discuss how the COVID-19 pandemic led to increases in NET use for safe management of cases with deferred surgery and adjuvant treatments. NET represents a safe and effective tool for the management of postmenopausal women with HR+/HER2- breast cancer, enabling disease downstaging and a wider range of surgical options. Aromatase inhibitors are the preferred NET, with evidence suggesting that longer regimens might yield optimal results. However, NET remains currently underutilised in many territories and institutions. Further validation of predictors for treatment response and benefit is needed to help standardise and fully exploit the potential of NET in the clinic.

oncology
Neoadjuvant chemotherapy combined with endocrine therapy for hormone receptor-positive breast cancer: A systematic review and meta-analysis

Hong-Fang Ma,Jun Shen,Bin Xu,Jian-Guo Shen

DOI: https://doi.org/10.1097/md.0000000000035928

IF: 1.6

2023-11-29

Medicine

Abstract:The incidence of breast cancer, the most commonly diagnosed malignant tumor in women, has surpassed lung cancer in incidence and continues to increase by 0.3% per year. [ 1 , 2 ] Surgical resection treatment is a common therapeutic approach for managing early-stage breast cancer in most patients. Currently, 2 main surgical options are available: mastectomy and breast-conserving surgery (BCS). A multicenter study conducted in an Asian population revealed that both BCS and mastectomy therapies resulted in similar survival rates. [ 3 ] However, a systematic review and meta-analysis conducted by Zehra et al [ 4 ] suggested that BCS offered superior health-related quality of life outcomes for breast cancer survivors compared to mastectomy. It's worth noting that approximately 4 out of 5 breast cancer patients are diagnosed as hormone receptor-positive (HR+). [ 5 ] For these patients, 2 key adjuvant-based treatment choices come into play, namely neoadjuvant chemotherapy (NCT) and endocrine therapy (NET). These treatments can be instrumental in facilitating BCS. [ 6 , 7 ] For instance, research by Botty Van den Bruele et al [ 8 ] showcased that NCT achieved nodal pathologic complete response in a majority of patients with occult primary breast cancer. Moreover, NET has been widely adopted for postmenopausal breast cancer, particularly for cases with estrogen receptor-positive (ER+), mirroring the role of NCT in HR+ breast cancer treatment. [ 9 ]

medicine, general & internal
Current Status of Neoadjuvant Endocrine Therapy in Early Stage Breast Cancer

Tomás Reinert,Rodrigo Gonçalves,Matthew J. Ellis

DOI: https://doi.org/10.1007/s11864-018-0538-9

2018-04-16

Current Treatment Options in Oncology

Abstract:Opinion statementNeoadjuvant endocrine therapy (NET) with Ki67-based response monitoring is a practical, cost-effective approach to the management of clinical stage II and III estrogen receptor-positive (ER+) breast cancer. In addition to marked improvements in rates of breast conservation, the identification of extreme responders on the basis of the preoperative endocrine prognostic index (PEPI) provides a rationale to avoid chemotherapy on the basis of highly favorable prognosis in some patients. Finally, samples accrued from patients treated with neoadjuvant therapy are providing valuable insights into the molecular basis for intrinsic resistance to endocrine therapy and promise a more rational basis and precise approach to the systemic treatment of ER+ breast cancer.

oncology
Long-term outcomes of neoadjuvant endocrine therapy versus chemotherapy in luminal HER2-breast cancer

N.K. Abduloeva,V.M. Moiseenko,F.V. Moiseenko,O.A. Skripko,M.V. Scriabin,R.A. Ryanjina

DOI: https://doi.org/10.31917/2501041

2024-03-30

Practical oncology

Abstract:Introduction. Neoadjuvant endocrine therapy (NET) is an effective treatment modality that can downsize breast tumors in a cohort of postmenopausal women with HR-positive HER2-negative breast cancer. A lack of data regarding efficacy of NET vs neoadjuvant cytotoxic chemotherapy (NCT) leads to limited usage of NET despite its favorable toxicity profile. Perioperative endocrine therapy is mainly used for the elderly or patients with comorbidities that limit their access to NCT. The COVID-19 pandemic led to increased data of NET efficacy. Nevertheless, long-term outcomes of NET application are underrepresented in literature. Objective. Assessment of long-term outcomes in patients treated with neoadjuvant endocrine therapy (NAT) versus neoadjuvant cytotoxic chemotherapy in a cohort of postmenopausal women with HR-positive HER2-negative breast cancer. Materials and methods. We retrospectively evaluated the results of treatment of 154postmenopausal patients with luminal HER2-breast cancer who were treated with neoadjuvant systemic therapy (NET or NCT) at the State Medical Institution «St. Petersburg Clinical Scientific and Practical Center for Specialized Types of Medical Care (Oncological)» from 01.01.2019 to 31.11.2020. We analyzed data on radiological, pathomorphological and long-term treatment outcomes (rate of locoregional and overall recurrence) in two groups.Results. 154 patients received neoadjuvant hormone therapy (n=78) or neoadjuvant chemotherapy (n=76). The clinical response was evaluated according to the RECIST criteria after 12 weeks and after study treatment using MMG. Partial or complete radiological response was achieved in 41.0% (n=32) in the NET group vs 69.7% (n=53) in the NCT group (p<0.001). All patients included in the study underwent surgery. A complete pathologic response was observed in 9.2% (n=7) of patients in the chemotherapy group, and in 0% of patients in the endocrine therapy group (p=0.006). Median follow-up was 46.2 months. Progression was recorded in 23.2% (n=29) of participants, with no significant benefit of NCT over NET in the frequency of locoregional relapses (NET n=8 (10.3%) vs NCT n=4 (5.3%)) (p= 0.369) or the occurrence of distant metastases NAT n=8 (10.3%) vs NCT n=13 (17.1%)) (p=0.216). Multivariate analysis showed that only pathologic lymph node status (ypN2–3) was an independent predictor of progression (p=0.007, OR=3.2; 95%CI: 1.380-7.422). Conclusions. Long-term outcomes after neoadjuvant hormone therapy are comparable with chemotherapy in the group of postmenopausal women with luminal HER2-breast cancer. The small sample size and limited follow-up period are significant limitations of our work.
Post-Neoadjuvant Treatment Strategies in Breast Cancer

Christiane Matuschek,Danny Jazmati,Edwin Bölke,Bálint Tamaskovics,Stefanie Corradini,Wilfried Budach,David Krug,Svjetlana Mohrmann,Eugen Ruckhäberle,Tanja Fehm,Carolin Nestle Krämling,Markus Dommach,Jan Haussmann

DOI: https://doi.org/10.3390/cancers14051246

2022-02-28

Abstract:Neoadjuvant chemotherapy enables close monitoring of tumor response in patients with breast cancer. Being able to assess tumor response during treatment provides an opportunity to evaluate new therapeutic strategies. Thus, for triple-negative breast tumors, it was demonstrated that additional immunotherapy could improve prognosis compared with chemotherapy alone. Furthermore, adjuvant therapy can be escalated or de-escalated correspondingly. The CREATE-X trial randomly assigned HER2-negative patients with residual tumor after neoadjuvant therapy to either observation or capecitabine. In HER2-negative patients with positive BRCA testing, the OlympiA study randomly assigned patients to either observation or olaparib. HER2-positive patients without pathologic remission were randomly assigned to trastuzumab or trastuzumab-emtansine within the KATHERINE study. These studies were all able to show an improvement in oncologic outcome associated with the escalation of therapy in patients presenting with residual tumor after neoadjuvant treatment. On the other hand, this individualization of therapy may also offer the possibility to de-escalate treatment, and thereby reduce morbidity. Among WSG-ADAPT HER2+/HR-, HER2-positive patients achieved comparable results without chemotherapy after complete remission following neoadjuvant treatment. In summary, the concept of post-neoadjuvant therapy constitutes a great opportunity for individualized cancer treatment, potentially improving outcome. In this review, the most important trials of post-neoadjuvant therapy are compiled and discussed.
Current and future role of neoadjuvant therapy for breast cancer

Michael Untch,Gottfried E. Konecny,Stefan Paepke,Gunter von Minckwitz

DOI: https://doi.org/10.1016/j.breast.2014.06.004

IF: 4.254

2014-10-01

The Breast

Abstract:Neoadjuvant systemic chemotherapy is a possible therapeutic approach for the treatment of locally advanced operable, primarily non-operable or inflammatory breast cancer. Neoadjuvant systemic chemotherapy is an option for breast cancer patients who would require adjuvant chemotherapy otherwise based on clinical and histological examination and imaging. The use of neoadjuvant systemic therapy in operable breast cancer is currently increasing because of its advantages that include higher rates of breast conserving surgery and the possibility of measuring early in-vivo response to systemic treatment. The timing of axillary sentinel lymph node diagnosis (i.e. before or after neoadjuvant chemotherapy) is critical in that it may influence the likelihood of axillary preservation. It is not yet clear if neoadjuvant therapy might improve outcomes in certain subgroups of breast cancer patients. Neoadjuvant treatment modalities require a close collaboration between oncology professionals, including surgeons, gynecologists, medical oncologists, radiation oncologists, radiologists and pathologists. The most important parameter for treatment success and improved overall survival is the achievement of a pathologic complete response (pCR), although the role of pCR in patients with luminal A like tumours might be less informative. Identification of patient subgroups with high pCR rates may allow less invasive surgical or radiological interventions. Patients not achieving a pCR may be candidates for postoperative clinical trials exploring novel systemic treatments.
Extended adjuvant endocrine therapy in hormone-receptor positive early breast cancer: current and future evidence

E J Blok,M G M Derks,J J M van der Hoeven,C J H van de Velde,J R Kroep

DOI: https://doi.org/10.1016/j.ctrv.2015.02.004

Abstract:The optimal duration and regimen of adjuvant hormonal therapy for premenopausal and postmenopausal patients with hormone receptor positive early breast cancer has not yet been established. This review will give an overview of published and ongoing studies concerning extended endocrine treatment. Most of the currently published studies are based on the adjuvant treatment regime of 5 years tamoxifen, which has been proven to be inferior compared to aromatase inhibitor (AI)-containing regimes. Therefore, until today, there is no clear evidence for the extension of endocrine therapy after upfront AI-based adjuvant treatment regimes. Multiple clinical trials, which will be discussed in this review, are ongoing to elucidate on this matter. We emphasize the need for tailoring of extended adjuvant endocrine treatment. The quest for predictive biomarkers, which are currently being investigated in the context of decision-making whether or not to start adjuvant chemotherapy, should be expanded to include the feasibility of extended endocrine treatment based on these markers. By tailoring the extension of endocrine treatment, overtreatment, side effects and unnecessary costs will be prevented.
Influence of norethynodrel with mestranol on intraocular pressure in glaucoma. II. A controlled double-blind study.

E. J. Meyer,C. R. Roberts,H. Leibowitz,B. McGowan,R. Houle

DOI: https://doi.org/10.1001/ARCHOPHT.1966.00970050773011

1966-06-01

A M A Archives of Ophthalmology

Abstract:We have recently reported 1 that daily oral administration of norethynodrel with mestranol, 5 mg, to patients with open-angle glaucoma appears in the course of two or more weeks to induce statistically significant reduction of intraocular pressure. To make sure that we had not recorded a nonspecific placebo effect rather than a pharmacological one, the present controlled, double-blind study was undertaken. Method Coded prescriptions for norethynodrel with mestranol, in dosage of 5 mg daily by mouth, were given to patients with open-angle glaucoma in the Glaucoma Consultation Service of the Massachusetts Eye and Ear Infirmary. Those whose tensions were dangerously elevated, who had extensive field defects, or who were considered unreliable were excluded from the study. Patients continued to receive whatever antiglaucoma therapy they were taking. Coded prescriptions for the study drug were filled by the hospital pharmacist who, unknown to patient and physician, substituted an inert but identically appearing placebo
Evaluation of neoadjuvant inhibition of aromatase activity and signal transduction in breast cancer

Louis Wing-Cheong Chow,Adrian Yun-San Yip,Wings Tjing-Yung Loo,Masakazu Toi

DOI: https://doi.org/10.1016/j.canlet.2007.12.003

2008-04-18

Abstract:Purpose: To evaluate the efficacy and safety of combing aromatase inhibitor (AI) and signal transduction inhibitor neoadjuvantly in postmenopausal patients with invasive hormone-sensitive breast cancer. Patients and methods: Postmenopausal women with hormone-sensitive breast cancer were given three months of letrozole 2.5mg daily and imatinib 400mg twice daily preoperatively. End-points of this study included clinical and pathologic responses, toxicities, and change in [(18)F]fluorodeoxyglucose (FDG) uptake in tumor. Expression of c-Kit was also evaluated in breast cancer tissue by immunostaining. Results: Thirteen patients, aged 52--78, were accrued. Five patients (38.5%) experienced grade 3 toxicity including neutropenia, skin rash, dermatitis, hypokalemia, shortness of breath, acute coronary syndrome, and acute chronic gastritis. Three patients were withdrawn after two months of treatment due to hematoma in tumor and toxicity. Of the ten evaluable patients, nine patients (90%) achieved clinical partial response and one patient (10%) had stable disease. One patient (10%) achieved pathologic complete response. Average relative changes of FDG uptake was -69.5% among responders. Eight out of 13 tissue samples were tested for c-Kit expression and the expression was detected in all. Conclusions: In this pilot study, the dramatic response to this neoadjuvant combination treatment warrants further clinical trials. Further investigation on the involvement of c-Kit pathway in the treatment response is also suggested. However, dosage reduction of imatinib may be required to avoid its potential toxicity.
Coherent Signals DOA Estimation in the Presence of Complex Noise

Yuexian Wang

Abstract:A new direction of arrival (DOA) estimation method is proposed for situations where coherent sources exist. With this algorithm,the coherent and incoherent sources are estimated separately. The coherent sources can be estimated by exploiting the symmetry of the array geometry to avoid a significant loss in array aperture and the high computation of the conventional transformation method based on spatial smoothing.The difference smoothing method, instead of forward/backward smoothing, is also used to reduce complex noise effects. Therefore,the algorithm is suitable for weak signal DOA estimation with a small number of antennas.Simulation results demonstrate the validity and effectiveness of the proposed method.
Efficacy of neoadjuvant endocrine therapy compared with neoadjuvant chemotherapy in pre-menopausal patients with oestrogen receptor-positive and HER2-negative, lymph node-positive breast cancer

Hee Jeong Kim,Woo Chul Noh,Eun Sook Lee,Yong Sik Jung,Lee Su Kim,Wonshik Han,Seok Jin Nam,Gyung -Yub Gong,Hwa Jung Kim,Sei Hyun Ahn

DOI: https://doi.org/10.1186/s13058-020-01288-5

2020-05-27

Breast Cancer Research

Abstract:Abstract Introduction Neoadjuvant endocrine therapy (NET) has demonstrated efficacy in post-menopausal patients with hormone-responsive breast cancer. This trial was designed to compare the efficacy of neoadjuvant chemotherapy (NCT) with NET in pre-menopausal breast cancer. Patients and methods In this prospective, randomised, phase III study, oestrogen receptor (ER)-positive, HER2-negative, and lymph node-positive pre-menopausal breast cancer patients were recruited from 7 hospitals in South Korea. Enrolled patients were randomly assigned (1:1) to receive 24 weeks of either NCT or NET with goserelin and tamoxifen. The primary purpose was to evaluate the non-inferiority of NET compared to NCT using clinical response, assessed by MRI. Besides, pathological complete response rate (pCR), changes in Ki-67 expression, breast conservation surgery (BCS) rate, and quality of life were included as secondary endpoints. Results A total of 187 patients were assigned to receive NCT ( n = 95) or NET ( n = 92), and 87 patients in each group completed treatments. More NCT patients had complete response or partial response than NET patients using MRI (NCT 83.7% vs. NET 52.9%, 95% CI 17.6–44.0, p < 0.001) and callipers (NCT 83.9% vs. NET 71.3%, 95% CI 0.4–24.9, p = 0.046). Three NCT patients (3.4%) and one NET patient (1.2%) showed pCR ( p < 0.005). No difference existed in the conversion rate of BCS (13.8% for NCT vs. 11.5% for NET, p = 0.531) and Ki-67 change ( p = 0.114) between the two groups. Nineteen NCT patients had treatment-related grade 3 or worse events compared with none in the NET group. Conclusions Better clinical responses were observed in pre-menopausal patients after 24 weeks of NCT compared to those observed after NET. Trial registration Clinicaltrials.gov , NCT01622361 . Registration June 19, 2012.

oncology
[Hormone therapy, chemotherapy and immunotherapy in breast carcinoma. The best strategy for your patient]

H G Sayer,K Höffken

2003-06-12

Abstract:Modern treatment of cancer of the breast is based on established prognostic factors (patient age, receptor status, tumor size, lymph node involvement, tumor grading), and thus takes the patient's individual risk profile into account. In addition to the antiestrogen, tamoxifen, new hormonal preparations, such as the aromatase inhibitors, hold out promise of improved results from adjuvant treatment in elderly women. In premenopausal women, additional hormone blockade by means of GnRH analogs is of advantage. Neoadjuvant (preoperative) chemotherapy protocols will enable rapid evaluation of new therapeutic options. When metastases have developed, treatment with hormonal drugs is indicated in the case of slowly progressing disease (low risk), while clinically progressive metastasization (high risk) requires cytostatic chemotherapy. Here, studies involving more recent substances with improved tolerability, and tumor-specific antibodies, confirm an improvement in the prognosis. The concentration of drug treatment in interdisciplinary centers is a necessary element of quality assurance and therapeutic optimization.

Involvement of LeMDR, an ATP-binding cassette protein gene, in shikonin transport and biosynthesis in Lithospermum erythrorhizon

EFFECT OF ADJUVANT ENDOCRINE THERAPY ON ESTROGEN RECEPTOR-NEGATIVE, PROGESTERONE RECEPTOR-POSITIVE AND HER2 NEGATIVE BREAST CANCER PATIENTS

Endocrine Therapy As Adjuvant or Neoadjuvant Therapy for Breast Cancer: Selecting the Best Agents, the Timing and Duration of Treatment

[Neoadjuvant endocrine therapy for locally advanced breast cancer]

Abstract P2-03-19: The efficacy of neoadjuvant endocrine therapy during the waiting period for surgery in postmenopausal hormone receptor positive breast cancer

Optimizing the Use of Neoadjuvant Endocrine Therapy

Phase 2 randomized trial of primary endocrine therapy versus chemotherapy in postmenopausal patients with estrogen receptor-positive breast cancer

Abstract ED01-01: Optimizing endocrine therapy in premenopausal women

[The use of GnRH analogues in early and advanced breast carcinomas].

Neoadjuvant endocrine therapy in postmenopausal women with HR+/HER2- breast cancer

Neoadjuvant chemotherapy combined with endocrine therapy for hormone receptor-positive breast cancer: A systematic review and meta-analysis

Current Status of Neoadjuvant Endocrine Therapy in Early Stage Breast Cancer

Long-term outcomes of neoadjuvant endocrine therapy versus chemotherapy in luminal HER2-breast cancer

Post-Neoadjuvant Treatment Strategies in Breast Cancer

Current and future role of neoadjuvant therapy for breast cancer

Extended adjuvant endocrine therapy in hormone-receptor positive early breast cancer: current and future evidence

Influence of norethynodrel with mestranol on intraocular pressure in glaucoma. II. A controlled double-blind study.

Evaluation of neoadjuvant inhibition of aromatase activity and signal transduction in breast cancer

Coherent Signals DOA Estimation in the Presence of Complex Noise

Efficacy of neoadjuvant endocrine therapy compared with neoadjuvant chemotherapy in pre-menopausal patients with oestrogen receptor-positive and HER2-negative, lymph node-positive breast cancer

[Hormone therapy, chemotherapy and immunotherapy in breast carcinoma. The best strategy for your patient]